Relationship Between Biological Profiles and Clinical Evolutions Within the Same Cluster COVID-19 (COVIDCOLLECT)

Covid19 Clinical Trial

— COVIDCOLLECT  

Official title:

Biological Collection for the Study of the Relationship Between the Biological Profiles Observed and the Clinical Evolutions Within the Same Cluster of Transmission of the Coronavirus SARS-CoV-2

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04597736
• Other study ID #: RBPH 2020 HENQUELL
• Secondary ID: 2020-A02381-38
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 2020
• Est. completion date: February 2022

Study information

• Verified date: September 2020
• Source: University Hospital, Clermont-Ferrand
• Contact: Lise LACLAUTRE
• Phone: +33473754963
• Email: promo_interne_drci[@]chu-clermontferrand.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The hypothesis is that from a cluster defined by a confirmed positive case of COVID-19 and its contact cases, it is possible to study the different expressions and clinical evolutions of COVID-19 infection and to explore the biological profiles related to the observed clinical history. Certain biological determinants (virological, immunological, microbological or gentic) could indeed be correlated with the clinical presentation and/or be useful for personalized care. The main objective is to study the relationship between the biological profiles observed and the clinical evolutions within the same cluster of transmission of the coronavirus SARS-CoV-2 (positive COVID-19 cases and contact subjects).

Description:

Subjects with a COVID-19 infection and thei contact cases (identification according to health insurance criteria, see "Améli.fr") will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel. For the main objective: during the D0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine. For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: February 2022
• Est. primary completion date: November 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Child or adult, no age limit
• Able to give informed consent to participate in research
• If a minor participant: consent of the legal representatives
• If confirmed case COVID-19 (symptomatic or asymptomatic): laboratory result confirming infection with SARS-CoV-2 by RT-PCR or by serology
• If contact case: people identified as a risk contact according to the criteria of the "Amélie.fr" health insurance

Exclusion Criteria:

• Subjects under tutorship, curatorship, deprived of liberty, safeguard of justice
• Refusal of the child
• Refusal of participation

Related Conditions & MeSH terms

• Contact Case
• Covid19

Intervention

Biological:
• Biological collection with nasopharyngeal samples, saliva, blood, stool and urine
Subjects with a COVID-19 infection and their contact cases (identification according to health insurance criteria, see "Améli.fr") will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel. For the main objective: during the Day0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine. For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology.

Locations

Country	Name	City	State
France	CHU de Clermont-Ferrand	Clermont-Ferrand

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Virological profile	Nasopharyngeal SARS-CoV-2 viral load at day 0 by RT-PCR (in log or ?CT)	Day 0
Primary	Virological profile	Nasopharyngeal SARS-CoV-2 viral load at day 0 by RT-PCR (in log or ?CT)	Day 10
Primary	Virological profile	Nasopharyngeal SARS-CoV-2 viral load at day 0 by RT-PCR (in log or ?CT)	Day 21
Primary	Virological profile (serology)	SARS-CoV-2 serology by enzyme-linked immunosorbent assays or magnetic chemiluminescence enzyme immunoassay (IgG and IgM titers)	Day 0
Primary	Virological profile (serology)	SARS-CoV-2 serology by enzyme-linked immunosorbent assays or magnetic chemiluminescence enzyme immunoassay (IgG and IgM titers)	Day 10
Primary	Virological profile (serology)	SARS-CoV-2 serology by enzyme-linked immunosorbent assays or magnetic chemiluminescence enzyme immunoassay (IgG and IgM titers)	Day 21
Primary	Immunological profile with blood level for markers of inflammation (cytokine)	cytokine panel by flow cytometry or enzyme-linked immunosorbent assay in pg/mL	Day 0
Primary	Immunological profile with blood level for markers of inflammation (cytokine)	cytokine panel by flow cytometry or enzyme-linked immunosorbent assay in pg/mL	Day 10
Primary	Immunological profile with blood level for markers of inflammation (cytokine)	cytokine panel by flow cytometry or enzyme-linked immunosorbent assay in pg/mL	Day 21
Primary	Immunological profile with blood level for markers of inflammation	markers on immune cell subpopulation by RT-PCR or flow cytometry in CT value or %	Day 0
Primary	Immunological profile with blood level for markers of inflammation	markers on immune cell subpopulation by RT-PCR or flow cytometry in CT value or %	Day 10
Primary	Immunological profile with blood level for markers of inflammation	markers on immune cell subpopulation by RT-PCR or flow cytometry in CT value or %	Day 21
Primary	Biochemical profile by blood dosage of CRP	CRP in mg/l	Day 0
Primary	Biochemical profile by blood dosage of CRP	CRP in mg/l	Day 10
Primary	Biochemical profile by blood dosage of CRP	CRP in mg/l	Day 21
Primary	Biochemical profile by blood dosage of CRP	CRP in mg/l	Day 90
Primary	Biochemical profile by blood dosage of ASAT/ALAT	ASAT/ALAT in U/L	Day 0
Primary	Biochemical profile by blood dosage of ASAT/ALAT	ASAT/ALAT in U/L	Day 10
Primary	Biochemical profile by blood dosage of ASAT/ALAT	ASAT/ALAT in U/L	Day 21
Primary	Biochemical profile by blood dosage of ASAT/ALAT	ASAT/ALAT in U/L	Day 90
Primary	Biochemical profile by blood dosage of LDH	LDH in U/L	Day 0
Primary	Biochemical profile by blood dosage of LDH	LDH in U/L	Day 10
Primary	Biochemical profile by blood dosage of LDH	LDH in U/L	Day 21
Primary	Biochemical profile by blood dosage of LDH	LDH in U/L	Day 90
Primary	Biochemical profile by blood dosage of Lactate	Lactate in mg/l	Day 0
Primary	Biochemical profile by blood dosage of Lactate	Lactate in mg/l	Day 10
Primary	Biochemical profile by blood dosage of Lactate	Lactate in mg/l	Day 21
Primary	Biochemical profile by blood dosage of Lactate	Lactate in mg/l	Day 90
Primary	Biochemical profile by blood dosage of D-Dimer	D-Dimer in µg/L	Day 0
Primary	Biochemical profile by blood dosage of D-Dimer	D-Dimer in µg/L	Day 10
Primary	Biochemical profile by blood dosage of D-Dimer	D-Dimer in µg/L	Day 21
Primary	Biochemical profile by blood dosage of D-Dimer	D-Dimer in µg/L	Day 90
Primary	Biochemical profile by blood dosage of Troponin	Troponin in µg/L	Day 0
Primary	Biochemical profile by blood dosage of Troponin	Troponin in µg/L	Day 10
Primary	Biochemical profile by blood dosage of Troponin	Troponin in µg/L	Day 21
Primary	Biochemical profile by blood dosage of Troponin	Troponin in µg/L	Day 90
Primary	Biochemical profile by blood dosage of Ferritin	Ferritin in µg/L	Day 0
Primary	Biochemical profile by blood dosage of Ferritin	Ferritin in µg/L	Day 10
Primary	Biochemical profile by blood dosage of Ferritin	Ferritin in µg/L	Day 21
Primary	Biochemical profile by blood dosage of RAGE	RAGE (receptor of advanced end glycation products) by enzyme-linked immunosorbent assays in pg/mg total protein	Day 0
Primary	Biochemical profile by blood dosage of RAGE	RAGE (receptor of advanced end glycation products) by enzyme-linked immunosorbent assays in pg/mg total protein	Day 10
Primary	Biochemical profile by blood dosage of RAGE	RAGE (receptor of advanced end glycation products) by enzyme-linked immunosorbent assays in pg/mg total protein	Day 21
Primary	Biochemical profile by blood dosage of SUPAR	SUPAR (soluble urokinase plasminogen activator receptor) by enzyme-linked immunosorbent assays in pg/mg total protein	Day 0
Primary	Biochemical profile by blood dosage of SUPAR	SUPAR (soluble urokinase plasminogen activator receptor) by enzyme-linked immunosorbent assays in pg/mg total protein	Day 10
Primary	Biochemical profile by blood dosage of SUPAR	SUPAR (soluble urokinase plasminogen activator receptor) by enzyme-linked immunosorbent assays in pg/mg total protein	Day 21
Primary	Haematological profile by blood dosage of leukocytes	leukocytes in Giga/L	Day 0
Primary	Haematological profile by blood dosage of leukocytes	leukocytes in Giga/L	Day 10
Primary	Haematological profile by blood dosage of leukocytes	leukocytes in Giga/L	Day 21
Primary	Haematological profile by blood dosage of leukocytes	leukocytes in Giga/L	Day 90
Primary	Haematological profile by blood dosage of Red blood cells	Red blood cells in Tera/L	Day 0
Primary	Haematological profile by blood dosage of Red blood cells	Red blood cells in Tera/L	Day 10
Primary	Haematological profile by blood dosage of Red blood cells	Red blood cells in Tera/L	Day 21
Primary	Haematological profile by blood dosage of Red blood cells	Red blood cells in Tera/L	Day 90
Primary	Haematological profile by blood dosage of Hemoglobin	Hemoglobin in g/dL	Day 0
Primary	Haematological profile by blood dosage of Hemoglobin	Hemoglobin in g/dL	Day 10
Primary	Haematological profile by blood dosage of Hemoglobin	Hemoglobin in g/dL	Day 21
Primary	Haematological profile by blood dosage of Hemoglobin	Hemoglobin in g/dL	Day 90
Primary	Haematological profile by blood dosage of Hematocrit	Hematocrit in %	Day 0
Primary	Haematological profile by blood dosage of Hematocrit	Hematocrit in %	Day 10
Primary	Haematological profile by blood dosage of Hematocrit	Hematocrit in %	Day 21
Primary	Haematological profile by blood dosage of Hematocrit	Hematocrit in %	Day 90
Primary	Haematological profile by blood dosage of Mean corpuscular volume	Mean corpuscular volume in fL	Day 0
Primary	Haematological profile by blood dosage of Mean corpuscular volume	Mean corpuscular volume in fL	Day 10
Primary	Haematological profile by blood dosage of Mean corpuscular volume	Mean corpuscular volume in fL	Day 21
Primary	Haematological profile by blood dosage of Mean corpuscular volume	Mean corpuscular volume in fL	Day 90
Primary	Haematological profile by blood dosage of Mean corpuscular hemoglobin	Mean corpuscular hemoglobin in pg	Day 0
Primary	Haematological profile by blood dosage of Mean corpuscular hemoglobin	Mean corpuscular hemoglobin in pg	Day 10
Primary	Haematological profile by blood dosage of Mean corpuscular hemoglobin	Mean corpuscular hemoglobin in pg	Day 21
Primary	Haematological profile by blood dosage of Mean corpuscular hemoglobin	Mean corpuscular hemoglobin in pg	Day 90
Primary	Haematological profile by blood dosage of average corpuscular concentration of haemoglobin	Average corpuscular concentration of haemoglobin in g/dL	Day 0
Primary	Haematological profile by blood dosage of average corpuscular concentration of haemoglobin	Average corpuscular concentration of haemoglobin in g/dL	Day 10
Primary	Haematological profile by blood dosage of average corpuscular concentration of haemoglobin	Average corpuscular concentration of haemoglobin in g/dL	Day 21
Primary	Haematological profile by blood dosage of average corpuscular concentration of haemoglobin	Average corpuscular concentration of haemoglobin in g/dL	Day 90
Primary	Haematological profile by blood dosage of polynuclear neutrophil	polynuclear neutrophil in Giga/L	Day 0
Primary	Haematological profile by blood dosage of polynuclear neutrophil	polynuclear neutrophil in Giga/L	Day 10
Primary	Haematological profile by blood dosage of polynuclear neutrophil	polynuclear neutrophil in Giga/L	Day 21
Primary	Haematological profile by blood dosage of polynuclear neutrophil	polynuclear neutrophil in Giga/L	Day 90
Primary	Haematological profile by blood dosage of polynuclear eosinophils	polynuclear eosinophils in Giga/L	Day 0
Primary	Haematological profile by blood dosage of polynuclear eosinophils	polynuclear eosinophils in Giga/L	Day 10
Primary	Haematological profile by blood dosage of polynuclear eosinophils	polynuclear eosinophils in Giga/L	Day 21
Primary	Haematological profile by blood dosage of polynuclear eosinophils	polynuclear eosinophils in Giga/L	Day 90
Primary	Haematological profile by blood dosage of polynuclear basophils	polynuclear basophils in Giga/L	Day 0
Primary	Haematological profile by blood dosage of polynuclear basophils	polynuclear basophils in Giga/L	Day 10
Primary	Haematological profile by blood dosage of polynuclear basophils	polynuclear basophils in Giga/L	Day 21
Primary	Haematological profile by blood dosage of polynuclear basophils	polynuclear basophils in Giga/L	Day 90
Primary	Haematological profile by blood dosage of lymphocytes	lymphocytes in Giga/L	Day 0
Primary	Haematological profile by blood dosage of lymphocytes	lymphocytes in Giga/L	Day 10
Primary	Haematological profile by blood dosage of lymphocytes	lymphocytes in Giga/L	Day 21
Primary	Haematological profile by blood dosage of lymphocytes	lymphocytes in Giga/L	Day 90
Primary	Haematological profile by blood dosage of monocytes	monocytes in Giga/L	Day 90
Primary	Haematological profile by blood dosage of monocytes	monocytes in Giga/L	Day 0
Primary	Haematological profile by blood dosage of monocytes	monocytes in Giga/L	Day 10
Primary	Haematological profile by blood dosage of monocytes	monocytes in Giga/L	Day 21
Primary	Haematological profile by blood dosage of platelets	platelets in Giga/L	Day 0
Primary	Haematological profile by blood dosage of platelets	platelets in Giga/L	Day 10
Primary	Haematological profile by blood dosage of platelets	platelets in Giga/L	Day 21
Primary	Haematological profile by blood dosage of platelets	platelets in Giga/L	Day 90
Primary	Haematological profile by blood dosage of activated partial thromboplastin time	activated partial thromboplastin time in second/witness	Day 0
Primary	Haematological profile by blood dosage of activated partial thromboplastin time	activated partial thromboplastin time in second/witness	Day 10
Primary	Haematological profile by blood dosage of activated partial thromboplastin time	activated partial thromboplastin time in second/witness	Day 21
Primary	Haematological profile by blood dosage of activated partial thromboplastin time	activated partial thromboplastin time in second/witness	Day 90
Primary	Haematological profile by blood dosage of fibrinogen	fibrinogen in g/L	Day 0
Primary	Haematological profile by blood dosage of fibrinogen	fibrinogen in g/L	Day 10
Primary	Haematological profile by blood dosage of fibrinogen	fibrinogen in g/L	Day 21
Primary	Haematological profile by blood dosage of fibrinogen	fibrinogen in g/L	Day 90
Primary	Haematological profile by blood dosage of factor V	factor V in %	Day 0
Primary	Haematological profile by blood dosage of factor V	factor V in %	Day 10
Primary	Haematological profile by blood dosage of factor V	factor V in %	Day 21
Primary	Haematological profile by blood dosage of factor V	factor V in %	Day 90
Secondary	SARS-CoV-2 salivary viral load	RT-PCR SARS-CoV-2 on saliva in ?CT value or log10 copies per mL	Day 0
Secondary	SARS-CoV-2 salivary viral load	RT-PCR SARS-CoV-2 on saliva in ?CT value or log10 copies per mL	Day 10
Secondary	SARS-CoV-2 salivary viral load	RT-PCR SARS-CoV-2 on saliva in ?CT value or log10 copies per mL	Day 21
Secondary	Comparison of viral sequences	bioinformatic and statistical analyzes of viral sequences (arbitrary unit and p-values)	Day 0
Secondary	Comparison of viral sequences	bioinformatic and statistical analyzes of viral sequences (arbitrary unit and p-values)	Day 10
Secondary	Comparison of viral sequences	bioinformatic and statistical analyzes of viral sequences (arbitrary unit and p-values)	Day 21
Secondary	microbiota analysis	bioinformatic and statistical analyzes of microbiota (arbitrary unit and p-values)	Day 0
Secondary	microbiota analysis	bioinformatic and statistical analyzes of microbiota (arbitrary unit and p-values)	Day 10
Secondary	microbiota analysis	bioinformatic and statistical analyzes of microbiota (arbitrary unit and p-values)	Day 21
Secondary	environmental and societal factors (EPICE)	EPICE score (Assessment of precariousness and health inequalities in examination centers Health) at day 0 from 0 to 100	Day 0
Secondary	environmental and societal factors	eating habits	Day 0
Secondary	environmental and societal factors	eating habits	day 10
Secondary	environmental and societal factors	eating habits	day 21
Secondary	environmental and societal factors	eating habits	day 90
Secondary	environmental and societal factors (SF-36)	SF-36 score (quality of life by Gardenal O) from 0 to 100	Day 0
Secondary	environmental and societal factors (SF-36)	SF-36 score (quality of life by Gardenal O) from 0 to 100	day 10
Secondary	environmental and societal factors (SF-36)	SF-36 score (quality of life by Gardenal O) from 0 to 100	day 21
Secondary	environmental and societal factors (SF-36)	SF-36 score (quality of life by Gardenal O) from 0 to 100	day 90
Secondary	environmental and societal factors (Physical activity)	Physical activity score (by J. Ricci et L. Gagnon test for adults and ActiFitY test for children) from 0 to 100	Day 0
Secondary	environmental and societal factors (Physical activity)	Physical activity score (by J. Ricci et L. Gagnon test for adults and ActiFitY test for children) from 0 to 100	day 10
Secondary	environmental and societal factors (Physical activity)	Physical activity score (by J. Ricci et L. Gagnon test for adults and ActiFitY test for children) from 0 to 100	day 21
Secondary	environmental and societal factors (Physical activity)	Physical activity score (by J. Ricci et L. Gagnon test for adults and ActiFitY test for children) from 0 to 100	day 90
Secondary	body weight	body weight in kg	Day 0
Secondary	body weight	body weight in kg	day 10
Secondary	body weight	body weight in kg	day 21
Secondary	body weight	body weight in kg	day 90
Secondary	oxygen saturation	oxygen saturation in %	Day 0
Secondary	oxygen saturation	oxygen saturation in %	day 10
Secondary	oxygen saturation	oxygen saturation in %	day 21
Secondary	oxygen saturation	oxygen saturation in %	day 90
Secondary	Respiratory rate	Respiratory rate per minute	Day 0
Secondary	Respiratory rate	Respiratory rate per minute	day 10
Secondary	Respiratory rate	Respiratory rate per minute	day 21
Secondary	Respiratory rate	Respiratory rate per minute	day 90
Secondary	cardiac frequency	cardiac frequency per minute	Day 0
Secondary	cardiac frequency	cardiac frequency per minute	day 10
Secondary	cardiac frequency	cardiac frequency per minute	day 21
Secondary	cardiac frequency	cardiac frequency per minute	day 90
Secondary	lung damage	Lung damage on auscultation in terms of presence/absence	Day 0
Secondary	lung damage	Lung damage on auscultation in terms of presence/absence	day 10
Secondary	lung damage	Lung damage on auscultation in terms of presence/absence	day 21
Secondary	lung damage	Lung damage on auscultation in terms of presence/absence	day 90
Secondary	lung evolution	CT san in terms of normal/abnormal (children and pregnant women not concerned)	day 90
Secondary	blood pressure	Dysatolic/systolic blood pressure in mmHg	Day 0
Secondary	blood pressure	Dysatolic/systolic blood pressure in mmHg	day 10
Secondary	blood pressure	Dysatolic/systolic blood pressure in mmHg	day 21
Secondary	blood pressure	Dysatolic/systolic blood pressure in mmHg	day 90
Secondary	body temperature	Body temperature in °C	Day 0
Secondary	body temperature	Body temperature in °C	day 10
Secondary	body temperature	Body temperature in °C	day 21
Secondary	body temperature	Body temperature in °C	day 90
Secondary	clinical exam (skin)	Skin mottling in terms of presence/absence	Day 0
Secondary	clinical exam (skin)	Skin mottling in terms of presence/absence	day 10
Secondary	clinical exam (skin)	Skin mottling in terms of presence/absence	day 21
Secondary	clinical exam (skin)	Skin mottling in terms of presence/absence	day 90
Secondary	clinical exam (polypnea)	polypnea in terms of presence/absence	Day 0
Secondary	clinical exam (polypnea)	polypnea in terms of presence/absence	day 10
Secondary	clinical exam (polypnea)	polypnea in terms of presence/absence	day 21
Secondary	clinical exam (polypnea)	polypnea in terms of presence/absence	day 90
Secondary	denutrition	denutrition in terms of presence/absence	Day 0
Secondary	denutrition	denutrition in terms of presence/absence	day 10
Secondary	denutrition	denutrition in terms of presence/absence	day 21
Secondary	denutrition	denutrition in terms of presence/absence	day 90
Secondary	Antibiotic treatment	Antibiotic treatment in terms of presence/absence with precision if necessary	Day 0
Secondary	Antibiotic treatment	Antibiotic treatment in terms of presence/absence with precision if necessary	day 10
Secondary	Antibiotic treatment	Antibiotic treatment in terms of presence/absence with precision if necessary	day 21
Secondary	Antibiotic treatment	Antibiotic treatment in terms of presence/absence with precision if necessary	day 90
Secondary	Steroidal anti-inflammatory treatment	Steroidal anti-inflammatory treatment in terms of presence/absence with precision if necessary	Day 0
Secondary	Steroidal anti-inflammatory treatment	Steroidal anti-inflammatory treatment in terms of presence/absence with precision if necessary	day 10
Secondary	Steroidal anti-inflammatory treatment	Steroidal anti-inflammatory treatment in terms of presence/absence with precision if necessary	day 21
Secondary	Steroidal anti-inflammatory treatment	Steroidal anti-inflammatory treatment in terms of presence/absence with precision if necessary	day 90
Secondary	Anti-diabetic treatment	Anti-diabetic treatment in terms of presence/absence with precision if necessary	Day 0
Secondary	Anti-diabetic treatment	Anti-diabetic treatment in terms of presence/absence with precision if necessary	day 10
Secondary	Anti-diabetic treatment	Anti-diabetic treatment in terms of presence/absence with precision if necessary	day 21
Secondary	Anti-diabetic treatment	Anti-diabetic treatment in terms of presence/absence with precision if necessary	day 90
Secondary	Gastric protector treatment	Gastric protector treatment in terms of presence/absence with precision if necessary	Day 0
Secondary	Gastric protector treatment	Gastric protector treatment in terms of presence/absence with precision if necessary	day 10
Secondary	Gastric protector treatment	Gastric protector treatment in terms of presence/absence with precision if necessary	day 21
Secondary	Gastric protector treatment	Gastric protector treatment in terms of presence/absence with precision if necessary	day 90
Secondary	chills	chills in terms of presence/absence	Day 0
Secondary	chills	chills in terms of presence/absence	day 10
Secondary	chills	chills in terms of presence/absence	day 21
Secondary	chills	chills in terms of presence/absence	day 90
Secondary	Myalgia	Myalgia in terms of presence/absence	Day 0
Secondary	Myalgia	Myalgia in terms of presence/absence	day 10
Secondary	Myalgia	Myalgia in terms of presence/absence	day 21
Secondary	Myalgia	Myalgia in terms of presence/absence	day 90
Secondary	Anorexia	Anorexia in terms of presence/absence	Day 0
Secondary	Anorexia	Anorexia in terms of presence/absence	day 10
Secondary	Anorexia	Anorexia in terms of presence/absence	day 21
Secondary	Anorexia	Anorexia in terms of presence/absence	day 90
Secondary	Rhinitis	Rhinitis in terms of presence/absence	Day 0
Secondary	Rhinitis	Rhinitis in terms of presence/absence	day 10
Secondary	Rhinitis	Rhinitis in terms of presence/absence	day 21
Secondary	Rhinitis	Rhinitis in terms of presence/absence	day 90
Secondary	Confusion	Confusion in terms of presence/absence	Day 0
Secondary	Confusion	Confusion in terms of presence/absence	day 10
Secondary	Confusion	Confusion in terms of presence/absence	day 21
Secondary	Confusion	Confusion in terms of presence/absence	day 90
Secondary	Asthenia	Asthenia in terms of presence/absence	Day 0
Secondary	Asthenia	Asthenia in terms of presence/absence	day 10
Secondary	Asthenia	Asthenia in terms of presence/absence	day 21
Secondary	Asthenia	Asthenia in terms of presence/absence	day 90
Secondary	Falls at home	Falls at home in terms of presence/absence	Day 0
Secondary	Falls at home	Falls at home in terms of presence/absence	day 10
Secondary	Falls at home	Falls at home in terms of presence/absence	day 21
Secondary	Falls at home	Falls at home in terms of presence/absence	day 90
Secondary	Insomnia	Insomnia in terms of presence/absence	Day 0
Secondary	Insomnia	Insomnia in terms of presence/absence	day 10
Secondary	Insomnia	Insomnia in terms of presence/absence	day 21
Secondary	Insomnia	Insomnia in terms of presence/absence	day 90
Secondary	Angina	Angina in terms of presence/absence	Day 0
Secondary	Angina	Angina in terms of presence/absence	day 10
Secondary	Angina	Angina in terms of presence/absence	day 21
Secondary	Angina	Angina in terms of presence/absence	day 90
Secondary	Ageusia	Ageusia in terms of presence/absence	Day 0
Secondary	Ageusia	Ageusia in terms of presence/absence	day 10
Secondary	Ageusia	Ageusia in terms of presence/absence	day 21
Secondary	Ageusia	Ageusia in terms of presence/absence	day 90
Secondary	Respiratory complaints	Respiratory complaints in term of SRIpr score from 0 to 100	Day 0
Secondary	Respiratory complaints	Respiratory complaints in term of SRIpr score from 0 to 100	day 2
Secondary	Respiratory complaints	Respiratory complaints in term of SRIpr score from 0 to 100	day 4
Secondary	Respiratory complaints	Respiratory complaints in term of SRIpr score from 0 to 100	day 6
Secondary	Respiratory complaints	Respiratory complaints in term of SRIpr score from 0 to 100	day 8
Secondary	Respiratory complaints	Respiratory complaints in term of SRIpr score from 0 to 100	day 10
Secondary	Respiratory complaints	Respiratory complaints in term of SRIpr score from 0 to 100	day 21
Secondary	Respiratory complaints	Respiratory complaints in term of SRIpr score from 0 to 100	day 90
Secondary	transmission rate	Rate of viral transmission determine by bioinformatic and statistical analyzes in %	Day 0
Secondary	transmission rate	Rate of viral transmission determine by bioinformatic and statistical analyzes in %	day 10
Secondary	transmission rate	Rate of viral transmission determine by bioinformatic and statistical analyzes in %	day 21
Secondary	prolonged viral shedding	Prolonged viral shedding evaluate by RT-PCR (CT value or log10 copies per mL)	between day 0 and day 21